116 related articles for article (PubMed ID: 2198807)
21. Immunity to and immunization against measles, rubella and mumps in patients after autologous bone marrow transplantation.
Pauksen K; Duraj V; Ljungman P; Sjölin J; Oberg G; Lönnerholm G; Fridell E; Smedmyr B; Simonsson B
Bone Marrow Transplant; 1992 Jun; 9(6):427-32. PubMed ID: 1628126
[TBL] [Abstract][Full Text] [Related]
22. [Immunization of healthy children with mumps-rubella bivalent live vaccine and simultaneous vaccination with mumps-rubella and varicella vaccines].
Takayama N; Kidokoro M; Suzuki K; Morita M
Kansenshogaku Zasshi; 1991 Oct; 65(10):1271-5. PubMed ID: 1791323
[TBL] [Abstract][Full Text] [Related]
23. [Age-related seroprevalence of measles, mumps and rubella antibodies in 1996].
Zäch K; Nicoara C; Germann D; Matter L
Schweiz Med Wochenschr; 1998 Apr; 128(17):649-57. PubMed ID: 9622837
[TBL] [Abstract][Full Text] [Related]
24. Comparative study and evaluation of further attenuated, live measles vaccines alone and in combination with mumps and rubella vaccines.
Wegmann A; Glück R; Just M; Mischler R; Paroz P; Germanier R
Dev Biol Stand; 1986; 65():69-74. PubMed ID: 3556778
[TBL] [Abstract][Full Text] [Related]
25. Serological evaluation of a measles, mumps, and rubella vaccine.
Robertson CM; Bennett VJ; Jefferson N; Mayon-White RT
Arch Dis Child; 1988 Jun; 63(6):612-6. PubMed ID: 3291787
[TBL] [Abstract][Full Text] [Related]
26. Persistence of antibody after administration of monovalent and combined live attenuated measles, mumps, and rubella virus vaccines.
Weibel RE; Buynak EB; McLean AA; Hilleman MR
Pediatrics; 1978 Jan; 61(1):5-11. PubMed ID: 263873
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of a two-dose measles, mumps, and rubella vaccination schedule in a cohort of college athletes.
Coté TR; Sivertson D; Horan JM; Lindegren ML; Dwyer DM
Public Health Rep; 1993; 108(4):431-5. PubMed ID: 8341775
[TBL] [Abstract][Full Text] [Related]
28. Safety and immunogenicity of a combined live attenuated measles, mumps, rubella, and varicella vaccine (MMR(II)V) in healthy children.
Watson BM; Laufer DS; Kuter BJ; Staehle B; White CJ; Starr SE
J Infect Dis; 1996 Mar; 173(3):731-4. PubMed ID: 8627041
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of mumps antibodies after measles-mumps-rubella (MMR) vaccines.
Ozaki K; Kuno-Sakai H; Kimura M
Tokai J Exp Clin Med; 1987 Dec; 12(5-6):305-11. PubMed ID: 3508655
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of vaccination of marrow transplant recipients with a live attenuated measles, mumps, and rubella vaccine.
Ljungman P; Fridell E; Lönnqvist B; Bolme P; Böttiger M; Gahrton G; Linde A; Ringdén O; Wahren B
J Infect Dis; 1989 Apr; 159(4):610-5. PubMed ID: 2647859
[TBL] [Abstract][Full Text] [Related]
31. Persistence of antibody in human subjects for 7 to 10 years following administration of combined live attenuated measles, mumps, and rubella virus vaccines.
Weibel RE; Buynak EB; McLean AA; Roehm RR; Hilleman MR
Proc Soc Exp Biol Med; 1980 Nov; 165(2):260-3. PubMed ID: 7443713
[No Abstract] [Full Text] [Related]
32. Clinical and laboratory studies of combined live measles, mumps, and rubella vaccines using the RA 27/3 rubella virus.
Weibel RE; Carlson AJ; Villarejos VM; Buynak EB; McLean AA; Hilleman MR
Proc Soc Exp Biol Med; 1980 Nov; 165(2):323-6. PubMed ID: 7443721
[No Abstract] [Full Text] [Related]
33. Protection of mumps in children with various underlying diseases: application of a live attenuated mumps and trivalent measles-rubella-mumps (MRM) vaccines in these children.
Kanesaki T; Baba K; Tsuda N; Yabuuchi H; Yamanishi K; Takahashi M
Biken J; 1986 Dec; 29(3-4):63-71. PubMed ID: 3304276
[TBL] [Abstract][Full Text] [Related]
34. Seroconversion rates to combined measles-mumps-rubella-varicella vaccine of children with upper respiratory tract infection.
Dennehy PH; Saracen CL; Peter G
Pediatrics; 1994 Oct; 94(4 Pt 1):514-6. PubMed ID: 7936862
[TBL] [Abstract][Full Text] [Related]
35. Effects and side effects of a new trivalent combined measles-mumps-rubella (MMR) vaccine.
Isozaki M; Kuno-Sakai H; Hoshi N; Takesue R; Takakura I; Kimura M; Hikino M; Mitsuda M
Tokai J Exp Clin Med; 1982 Sep; 7(5):547-50. PubMed ID: 7182947
[TBL] [Abstract][Full Text] [Related]
36. Immune response to Edmonston-Zagreb measles virus strain in monovalent and combined MMR vaccine.
Beck M; Smerdel S; Dedić I; Delimar N; Rajninger-Miholic M; Juzbasić M; Manhalter T; Vlatković R; Borcić B; Mihajić Z
Dev Biol Stand; 1986; 65():95-100. PubMed ID: 3556780
[TBL] [Abstract][Full Text] [Related]
37. The elimination of indigenous measles, mumps, and rubella from Finland by a 12-year, two-dose vaccination program.
Peltola H; Heinonen OP; Valle M; Paunio M; Virtanen M; Karanko V; Cantell K
N Engl J Med; 1994 Nov; 331(21):1397-402. PubMed ID: 7969278
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of a combined vaccine against measles-mumps-rubella produced on human diploid cells.
Just M; Berger R; Glück R; Wegmann A
Dev Biol Stand; 1986; 65():25-7. PubMed ID: 3549399
[TBL] [Abstract][Full Text] [Related]
39. [Duration of immunity and occurrence of secondary vaccine failure following vaccination against measles, mumps and rubella].
Trier H; Rønne T
Ugeskr Laeger; 1992 Jul; 154(29):2008-13. PubMed ID: 1509566
[TBL] [Abstract][Full Text] [Related]
40. [Field trial with a new human diploid cell vaccine (HDCV) against measles, mumps and rubella].
Just M; Berger R; Glück R; Wegmann A
Schweiz Med Wochenschr; 1985 Nov; 115(48):1727-30. PubMed ID: 4081704
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
